{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T03:23:58Z","timestamp":1794799438676,"version":"4.9.1"},"reference-count":48,"publisher":"American Association for Cancer Research (AACR)","issue":"10","license":[{"start":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T00:00:00Z","timestamp":1778803200000},"content-version":"vor","delay-in-days":93,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100032718","name":"Kura Oncology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100032718","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100029695","name":"Children\u2019s Cancer Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100029695","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001368","name":"V Foundation for Cancer Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001368","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100003287","name":"Rally Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100003287","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Summer\u2019s Way Foundation and Friends of TJ"},{"name":"Tap Cancer Out"}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,5,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>Hyperactive RAS signaling, induced by mutations in NRAS, HRAS, or KRAS, drives tumorigenesis in most PAX3\/7::FOXO1 fusion-negative rhabdomyosarcomas (FN-RMS). Despite the frequency of these mutations, indirect RAS pathway\u2013directed therapies have been ineffective for RAS-driven RMS. Farnesyltransferase (FTase) inhibitors (FTI), such as tipifarnib, inhibit HRAS membrane localization and blunt RAS effector signaling, leading to an antitumor effect in HRAS-mutant FN-RMS preclinical models. However, the effect is not durable. In this study, we investigated the mechanisms of adaptive resistance that limit the activity of FTIs, revealing that response to FTIs was limited by adaptive feedback reactivation of ERK signaling and upregulation of wild-type RAS. The combination of HRAS suppression with FTI and MEK inhibition impaired ERK reactivation and reduced ERK transcriptional output in HRAS-mutant RMS models. Cotargeting FTase and MEK restrained tumor progression and induced terminal myogenic differentiation. These findings highlight an effective combinatorial strategy and support its preclinical translation for patients with HRAS-mutant RMS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>Farnesyltransferase and MEK inhibition suppresses ERK reactivation, decreases tumor growth, and promotes myogenesis in HRAS-mutant rhabdomyosarcoma.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/0008-5472.can-25-2985","type":"journal-article","created":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T19:12:39Z","timestamp":1770837159000},"page":"2508-2521","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Combined Inhibition of HRAS and MEK Induces Tumor Regression and Restores Myogenic Differentiation in HRAS-Mutant Rhabdomyosarcoma"],"prefix":"10.1158","volume":"86","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9783-1657","authenticated-orcid":false,"given":"Patience","family":"Odeniyide","sequence":"first","affiliation":[{"name":"1Department of Oncology, Sidney Kimmel Comprehensive Cancer Center (SKCCC), Johns Hopkins University School of Medicine, Baltimore, Maryland."},{"name":"2Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, Maryland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-7256-0608","authenticated-orcid":false,"given":"Alyza","family":"Skaist","sequence":"additional","affiliation":[{"name":"1Department of Oncology, Sidney Kimmel Comprehensive Cancer Center (SKCCC), Johns Hopkins University School of Medicine, Baltimore, Maryland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-5958-7613","authenticated-orcid":false,"given":"Elizabeth","family":"Fenner","sequence":"additional","affiliation":[{"name":"1Department of Oncology, Sidney Kimmel Comprehensive Cancer Center (SKCCC), Johns Hopkins University School of Medicine, Baltimore, Maryland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-3070-3168","authenticated-orcid":false,"given":"Hanah","family":"Amirkhanian","sequence":"additional","affiliation":[{"name":"1Department of Oncology, Sidney Kimmel Comprehensive Cancer Center (SKCCC), Johns Hopkins University School of Medicine, Baltimore, Maryland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1437-9966","authenticated-orcid":false,"given":"Andrew","family":"Baker","sequence":"additional","affiliation":[{"name":"1Department of Oncology, Sidney Kimmel Comprehensive Cancer Center (SKCCC), Johns Hopkins University School of Medicine, Baltimore, Maryland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1268-9461","authenticated-orcid":false,"given":"Alla","family":"Lisok","sequence":"additional","affiliation":[{"name":"1Department of Oncology, Sidney Kimmel Comprehensive Cancer Center (SKCCC), Johns Hopkins University School of Medicine, Baltimore, Maryland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3909-9920","authenticated-orcid":false,"given":"Lindy","family":"Zhang","sequence":"additional","affiliation":[{"name":"1Department of Oncology, Sidney Kimmel Comprehensive Cancer Center (SKCCC), Johns Hopkins University School of Medicine, Baltimore, Maryland."},{"name":"2Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, Maryland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-3873-8206","authenticated-orcid":false,"given":"Lisa B.","family":"Fridman","sequence":"additional","affiliation":[{"name":"1Department of Oncology, Sidney Kimmel Comprehensive Cancer Center (SKCCC), Johns Hopkins University School of Medicine, Baltimore, Maryland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-4894-3709","authenticated-orcid":false,"given":"Rafael I.","family":"Rojas","sequence":"additional","affiliation":[{"name":"1Department of Oncology, Sidney Kimmel Comprehensive Cancer Center (SKCCC), Johns Hopkins University School of Medicine, Baltimore, Maryland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4740-8930","authenticated-orcid":false,"given":"Katie E.","family":"Hebron","sequence":"additional","affiliation":[{"name":"3Laboratory of Cell and Developmental Signaling, Center for Cancer Research, Frederick, Maryland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-7226-3819","authenticated-orcid":false,"given":"Christopher","family":"Davis","sequence":"additional","affiliation":[{"name":"4Division of Hematology\/Oncology, Department of Pediatrics, Indiana University School of Medicine, Riley Hospital for Children at Indiana University Health and Herman B. Wells Center for Pediatric Research, Indianapolis, Indiana."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5872-4656","authenticated-orcid":false,"given":"Xiaohu","family":"Zhang","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04pw6fb54","id-type":"ROR","asserted-by":"publisher"}],"name":"National Center for Advancing Translational Sciences 5 Division of Preclinical Innovation, , , Rockville, Maryland."},{"id":[{"id":"https:\/\/ror.org\/01cwqze88","id-type":"ROR","asserted-by":"publisher"}],"name":"National Institutes of Health 5 Division of Preclinical Innovation, , , Rockville, Maryland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-1313-5403","authenticated-orcid":false,"given":"Gabrielle","family":"Feldman","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04pw6fb54","id-type":"ROR","asserted-by":"publisher"}],"name":"National Center for Advancing Translational Sciences 5 Division of Preclinical Innovation, , , Rockville, Maryland."},{"id":[{"id":"https:\/\/ror.org\/01cwqze88","id-type":"ROR","asserted-by":"publisher"}],"name":"National Institutes of Health 5 Division of Preclinical Innovation, , , Rockville, Maryland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7655-657X","authenticated-orcid":false,"given":"Steven P.","family":"Angus","sequence":"additional","affiliation":[{"name":"4Division of Hematology\/Oncology, Department of Pediatrics, Indiana University School of Medicine, Riley Hospital for Children at Indiana University Health and Herman B. Wells Center for Pediatric Research, Indianapolis, Indiana."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9386-9001","authenticated-orcid":false,"given":"Craig J.","family":"Thomas","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04pw6fb54","id-type":"ROR","asserted-by":"publisher"}],"name":"National Center for Advancing Translational Sciences 5 Division of Preclinical Innovation, , , Rockville, Maryland."},{"id":[{"id":"https:\/\/ror.org\/01cwqze88","id-type":"ROR","asserted-by":"publisher"}],"name":"National Institutes of Health 5 Division of Preclinical Innovation, , , Rockville, Maryland."},{"id":[{"id":"https:\/\/ror.org\/040gcmg81","id-type":"ROR","asserted-by":"publisher"}],"name":"National Cancer Institute 6 Lymphoid Malignancies Branch, Center for Cancer Research, , , Bethesda, Maryland."},{"id":[{"id":"https:\/\/ror.org\/01cwqze88","id-type":"ROR","asserted-by":"publisher"}],"name":"National Institutes of Health 6 Lymphoid Malignancies Branch, Center for Cancer Research, , , Bethesda, Maryland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4823-9080","authenticated-orcid":false,"given":"Angelina V.","family":"Vaseva","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/009avj582","id-type":"ROR","asserted-by":"publisher"}],"name":"Oregon Health and Science University 7 Department of Pediatrics, Department of Cell, Developmental and Cancer Biology, Knight Cancer Institute, , Portland, Oregon."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5356-9426","authenticated-orcid":false,"given":"Marielle E.","family":"Yohe","sequence":"additional","affiliation":[{"name":"3Laboratory of Cell and Developmental Signaling, Center for Cancer Research, Frederick, Maryland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3204-342X","authenticated-orcid":false,"given":"Elana J.","family":"Fertig","sequence":"additional","affiliation":[{"name":"1Department of Oncology, Sidney Kimmel Comprehensive Cancer Center (SKCCC), Johns Hopkins University School of Medicine, Baltimore, Maryland."},{"name":"8Institute for Genome Sciences, University of Maryland School of Medicine, Baltimore, Maryland."},{"name":"9Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine, Baltimore, Maryland."},{"name":"10Division of Hematology\/Oncology, Department of Medicine, University of Maryland School of Medicine, Baltimore, Maryland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7116-0605","authenticated-orcid":false,"given":"Christine A.","family":"Pratilas","sequence":"additional","affiliation":[{"name":"1Department of Oncology, Sidney Kimmel Comprehensive Cancer Center (SKCCC), Johns Hopkins University School of Medicine, Baltimore, Maryland."},{"name":"2Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, Maryland."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2026,2,11]]},"reference":[{"key":"2026051503081110800_bib1","doi-asserted-by":"crossref","first-page":"4218","DOI":"10.1002\/cncr.24465","article-title":"Trends in childhood rhabdomyosarcoma incidence and survival in the United States, 1975-2005","volume":"115","author":"Ognjanovic","year":"2009","journal-title":"Cancer"},{"key":"2026051503081110800_bib2","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1126\/science.8383879","article-title":"Deficiency in rhabdomyosarcomas of a factor required for MyoD activity and myogenesis","volume":"259","author":"Tapscott","year":"1993","journal-title":"Science"},{"key":"2026051503081110800_bib3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41572-018-0051-2","article-title":"Rhabdomyosarcoma","volume":"5","author":"Skapek","year":"2019","journal-title":"Nat Rev Dis Primers"},{"key":"2026051503081110800_bib4","doi-asserted-by":"crossref","first-page":"2859","DOI":"10.1200\/JCO.20.03060","article-title":"Genomic classification and clinical outcome in rhabdomyosarcoma: a report from an international consortium","volume":"39","author":"Shern","year":"2021","journal-title":"J Clin Oncol"},{"key":"2026051503081110800_bib5","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1073\/pnas.80.2.383","article-title":"Isolation and preliminary characterization of the transforming gene of a human neuroblastoma cell line","volume":"80","author":"Shimizu","year":"1983","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026051503081110800_bib6","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1038\/2041104b0","article-title":"An unidentified virus which causes the rapid production of tumours in mice","volume":"204","author":"Harvey","year":"1964","journal-title":"Nature"},{"key":"2026051503081110800_bib7","first-page":"311","article-title":"Morphologic responses to a murine erythroblastosis virus","volume":"39","author":"Kirsten","year":"1967","journal-title":"J Natl Cancer Inst"},{"key":"2026051503081110800_bib8","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/1476-4598-4-41","article-title":"p21WAF1 expression induced by MEK\/ERK pathway activation or inhibition correlates with growth arrest, myogenic differentiation and onco-phenotype reversal in rhabdomyosarcoma cells","volume":"4","author":"Ciccarelli","year":"2005","journal-title":"Mol Cancer"},{"key":"2026051503081110800_bib9","doi-asserted-by":"crossref","first-page":"eaan4470","DOI":"10.1126\/scitranslmed.aan4470","article-title":"MEK inhibition induces MYOG and remodels super-enhancers in RAS-driven rhabdomyosarcoma","volume":"10","author":"Yohe","year":"2018","journal-title":"Sci Transl Med"},{"key":"2026051503081110800_bib10","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1126\/science.278.5341.1288","article-title":"Regulation of distinct stages of skeletal muscle differentiation by mitogen-activated protein kinases","volume":"278","author":"Bennett","year":"1997","journal-title":"Science"},{"key":"2026051503081110800_bib11","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1158\/1535-7163.MCT-21-0194","article-title":"Vertical inhibition of the RAF\u2013MEK\u2013ERK Cascade induces myogenic differentiation, apoptosis, and tumor regression in H\/NRASQ61X mutant Rhabdomyosarcoma","volume":"21","author":"Garcia","year":"2022","journal-title":"Mol Cancer Ther"},{"key":"2026051503081110800_bib12","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1158\/1078-0432.CCR-22-1646","article-title":"The combination of trametinib and ganitumab is effective in RAS-mutated PAX-fusion negative rhabdomyosarcoma models","volume":"29","author":"Hebron","year":"2023","journal-title":"Clin Cancer Res"},{"key":"2026051503081110800_bib13","first-page":"131","article-title":"Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro","volume":"61","author":"End","year":"2001","journal-title":"Cancer Res"},{"key":"2026051503081110800_bib14","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1200\/JCO.2004.10.112","article-title":"Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer","volume":"22","author":"Van Cutsem","year":"2004","journal-title":"J Clin Oncol"},{"key":"2026051503081110800_bib15","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1200\/JCO.2005.03.8638","article-title":"Phase I trial and pharmacokinetic study of the farnesyltransferase inhibitor tipifarnib in children with refractory solid tumors or neurofibromatosis type I and plexiform neurofibromas","volume":"24","author":"Widemann","year":"2006","journal-title":"J Clin Oncol"},{"key":"2026051503081110800_bib16","doi-asserted-by":"crossref","first-page":"14459","DOI":"10.1074\/jbc.272.22.14459","article-title":"K- and N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors","volume":"272","author":"Whyte","year":"1997","journal-title":"J Biol Chem"},{"key":"2026051503081110800_bib17","doi-asserted-by":"crossref","first-page":"4642","DOI":"10.1158\/0008-5472.CAN-17-1925","article-title":"Tipifarnib inhibits HRAS-driven dedifferentiated thyroid cancers","volume":"78","author":"Untch","year":"2018","journal-title":"Cancer Res"},{"key":"2026051503081110800_bib18","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1200\/JCO.20.02903","article-title":"Tipifarnib in head and neck squamous cell carcinoma with HRAS mutations","volume":"39","author":"Ho","year":"2021","journal-title":"J Clin Oncol"},{"key":"2026051503081110800_bib19","doi-asserted-by":"crossref","first-page":"2973","DOI":"10.1038\/s41388-022-02305-x","article-title":"Targeting farnesylation as a novel therapeutic approach in HRAS-mutant rhabdomyosarcoma","volume":"41","author":"Odeniyide","year":"2022","journal-title":"Oncogene"},{"key":"2026051503081110800_bib20","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1186\/s13059-014-0550-8","article-title":"Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2","volume":"15","author":"Love","year":"2014","journal-title":"Genome Biol"},{"key":"2026051503081110800_bib21","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1109\/TVCG.2014.2346248","article-title":"UpSet: visualization of intersecting sets","volume":"20","author":"Lex","year":"2014","journal-title":"IEEE Trans Vis Comput Graph"},{"key":"2026051503081110800_bib22","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.cels.2015.12.004","article-title":"The molecular signatures database hallmark gene set collection","volume":"1","author":"Liberzon","year":"2015","journal-title":"Cell Syst"},{"key":"2026051503081110800_bib23","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41698-018-0051-4","article-title":"A transcriptional MAPK pathway activity score (MPAS) is a clinically relevant biomarker in multiple cancer types","volume":"2","author":"Wagle","year":"2018","journal-title":"NPJ Precis Oncol"},{"key":"2026051503081110800_bib24","doi-asserted-by":"crossref","first-page":"110068","DOI":"10.1016\/j.isci.2024.110068","article-title":"Oxygen tension-dependent variability in the cancer cell kinome impacts signaling pathways and response to targeted therapies","volume":"27","author":"Adebayo","year":"2024","journal-title":"iScience"},{"key":"2026051503081110800_bib25","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1038\/s41588-020-0590-9","article-title":"Using antagonistic pleiotropy to design a chemotherapy-induced evolutionary trap to target drug resistance in cancer","volume":"52","author":"Lin","year":"2020","journal-title":"Nat Genet"},{"key":"2026051503081110800_bib26","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1073\/pnas.1311846111","article-title":"High-throughput combinatorial screening identifies drugs that cooperate with ibrutinib to kill activated B-cell-like diffuse large B-cell lymphoma cells","volume":"111","author":"Mathews Griner","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026051503081110800_bib27","doi-asserted-by":"crossref","first-page":"77","DOI":"10.3892\/etm.2022.11776","article-title":"CCL2 promotes proliferation, migration and angiogenesis through the MAPK\/ERK1\/2\/MMP9, PI3K\/AKT, Wnt\/\u03b2-catenin signaling pathways in HUVECs","volume":"25","author":"Peng","year":"2022","journal-title":"Exp Ther Med"},{"key":"2026051503081110800_bib28","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s12943-021-01355-1","article-title":"Targeting CXCR2 inhibits the progression of lung cancer and promotes therapeutic effect of cisplatin","volume":"20","author":"Cheng","year":"2021","journal-title":"Mol Cancer"},{"key":"2026051503081110800_bib29","doi-asserted-by":"crossref","first-page":"6854","DOI":"10.18632\/oncotarget.2269","article-title":"CD271 is a functional and targetable marker of tumor-initiating cells in head and neck squamous cell carcinoma","volume":"5","author":"Murillo-Sauca","year":"2014","journal-title":"Oncotarget"},{"key":"2026051503081110800_bib30","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1038\/35074604","article-title":"Activation of EphA receptor tyrosine kinase inhibits the Ras\/MAPK pathway","volume":"3","author":"Miao","year":"2001","journal-title":"Nat Cell Biol"},{"key":"2026051503081110800_bib31","doi-asserted-by":"crossref","first-page":"6328","DOI":"10.1074\/jbc.271.11.6328","article-title":"SOS phosphorylation and disassociation of the Grb2-SOS complex by the ERK and JNK signaling pathways","volume":"271","author":"Chen","year":"1996","journal-title":"J Biol Chem"},{"key":"2026051503081110800_bib32","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1158\/1078-0432.CCR-19-3523","article-title":"Vertical pathway inhibition overcomes adaptive feedback resistance to KRASG12C inhibition","volume":"26","author":"Ryan","year":"2020","journal-title":"Clin Cancer Res"},{"key":"2026051503081110800_bib33","first-page":"5483","article-title":"Mitogen-activated protein kinase kinase 4\/stress-activated protein\/Erk kinase 1 (MKK4\/SEK1), a prostate cancer metastasis suppressor gene encoded by human chromosome 17","volume":"59","author":"Yoshida","year":"1999","journal-title":"Cancer Res"},{"key":"2026051503081110800_bib34","doi-asserted-by":"crossref","first-page":"14489","DOI":"10.1074\/jbc.272.22.14489","article-title":"Characterization of the mitogen-activated protein kinase kinase 4 (MKK4)\/c-Jun NH2-terminal kinase 1 and MKK3\/p38 pathways regulated by MEK kinases 2 and 3. MEK kinase 3 activates MKK3 but does not cause activation of p38 kinase in vivo","volume":"272","author":"Deacon","year":"1997","journal-title":"J Biol Chem"},{"key":"2026051503081110800_bib35","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.cub.2014.11.054","article-title":"NDR functions as a physiological YAP1 kinase in the intestinal epithelium","volume":"25","author":"Zhang","year":"2015","journal-title":"Curr Biol"},{"key":"2026051503081110800_bib36","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.molcel.2006.03.027","article-title":"A phosphatase holoenzyme comprised of Shoc2\/Sur8 and the catalytic subunit of PP1 functions as an M-Ras effector to modulate Raf activity","volume":"22","author":"Rodriguez-Viciana","year":"2006","journal-title":"Mol Cell"},{"key":"2026051503081110800_bib37","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1038\/s43018-024-00800-6","article-title":"Co-targeting SOS1 enhances the antitumor effects of KRASG12C inhibitors by addressing intrinsic and acquired resistance","volume":"5","author":"Thatikonda","year":"2024","journal-title":"Nat Cancer"},{"key":"2026051503081110800_bib38","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/0092-8674(91)90460-G","article-title":"Protein farnesyltransferase and geranylgeranyltransferase share a common alpha subunit","volume":"65","author":"Seabra","year":"1991","journal-title":"Cell"},{"key":"2026051503081110800_bib39","doi-asserted-by":"crossref","first-page":"31141","DOI":"10.1074\/jbc.M504113200","article-title":"DHHC9 and GCP16 constitute a human protein fatty acyltransferase with specificity for H- and N-Ras","volume":"280","author":"Swarthout","year":"2005","journal-title":"J Biol Chem"},{"key":"2026051503081110800_bib40","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1128\/MCB.22.1.171-181.2002","article-title":"Absence of the CAAX endoprotease Rce1: effects on cell growth and transformation","volume":"22","author":"Bergo","year":"2002","journal-title":"Mol Cell Biol"},{"key":"2026051503081110800_bib41","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1056\/NEJMoa2303815","article-title":"Dabrafenib plus trametinib in pediatric glioma with BRAF V600 mutations","volume":"389","author":"Bouffet","year":"2023","journal-title":"N Engl J Med"},{"key":"2026051503081110800_bib42","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1158\/2159-8290.CD-23-1376","article-title":"Efficacy of the allosteric MEK inhibitor trametinib in relapsed and refractory juvenile myelomonocytic leukemia: a report from the Children's Oncology Group","volume":"14","author":"Stieglitz","year":"2024","journal-title":"Cancer Discov"},{"key":"2026051503081110800_bib43","doi-asserted-by":"publisher","first-page":"e51998","DOI":"10.3791\/51998","article-title":"The soft agar colony formation assay","author":"Borowicz","year":"2014","journal-title":"J Vis Exp"},{"key":"2026051503081110800_bib44","doi-asserted-by":"crossref","first-page":"6307","DOI":"10.1038\/s41467-024-50527-2","article-title":"Single cell transcriptomic profiling identifies tumor-acquired and therapy-resistant cell states in pediatric rhabdomyosarcoma","volume":"15","author":"Danielli","year":"2024","journal-title":"Nat Commun"},{"key":"2026051503081110800_bib45","doi-asserted-by":"crossref","first-page":"6403","DOI":"10.1073\/pnas.89.14.6403","article-title":"Isoprenoid addition to Ras protein is the critical modification for its membrane association and transforming activity","volume":"89","author":"Kato","year":"1992","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026051503081110800_bib46","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1038\/sj.onc.1210421","article-title":"MAP kinase signalling pathways in cancer","volume":"26","author":"Dhillon","year":"2007","journal-title":"Oncogene"},{"key":"2026051503081110800_bib47","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.molcel.2004.11.055","article-title":"Regulation of Raf-1 by direct feedback phosphorylation","volume":"17","author":"Dougherty","year":"2005","journal-title":"Mol Cell"},{"key":"2026051503081110800_bib48","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1038\/s41586-022-05086-1","article-title":"Structure of the MRAS-SHOC2-PP1C phosphatase complex","volume":"609","author":"Hauseman","year":"2022","journal-title":"Nature"}],"container-title":["Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/doi\/10.1158\/0008-5472.CAN-25-2985\/3737420\/can-25-2985.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/86\/10\/2508\/3790540\/can-25-2985.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/86\/10\/2508\/3790540\/can-25-2985.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T07:08:24Z","timestamp":1778828904000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerres\/article\/86\/10\/2508\/784891\/Combined-Inhibition-of-HRAS-and-MEK-Induces-Tumor"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,11]]},"references-count":48,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,2,11]]},"published-print":{"date-parts":[[2026,5,15]]}},"URL":"https:\/\/doi.org\/10.1158\/0008-5472.can-25-2985","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/0008-5472.32716670","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.32716751","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.32716854","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.32715503","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.32715834","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.32716464","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.32715725","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.32716347","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.32713726","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.32740842","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.32715500","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.32730814","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.32715893","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.32715326","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.32716461","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.32716851","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.32716754","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.32716350","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.32715837","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.32715728","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.32715988","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.32716673","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.32715879","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.32715896","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.32715985","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.32715882","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.32730811","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.32715323","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.32740845","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.32713729","asserted-by":"object"}]},"ISSN":["0008-5472","1538-7445"],"issn-type":[{"value":"0008-5472","type":"print"},{"value":"1538-7445","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,11]]}}}